Piper Sandler raised its price target on Ardelyx Inc (NASDAQ: ARDX) to $8 from $3 and upgraded to Overweight from a Neutral rating.
The upgrade follows a surprisingly positive advisory committee vote of 9-4 in favor of tenapanor as monotherapy and 10-2 (1 abstention) as combo therapy for controlling serum phosphorus in dialysis-dependent chronic kidney disease (CKD).
While we found the vote itself remarkable, it was more meaningful that the vote was not split along “party lines,” the analyst wrote.
To a significant surprise, the FDA issued a CRL in July 2021 in this indication, despite the company having run two large, positive Phase 3 trials with the FDA’s input on the design and execution of those trials.
In a rare sequence of events, ARDX appealed the CRL, got its day in court, and now, yet another rejection is still very much a possibility. FDA could ask for more data in the combo treatment setting.
If granted, the company will resubmit the NDA, which would undergo a two or six month-review. The exact timing for potential resubmission is not clear at this point. For now, Piper models a ~YE23 approval and 2024 launch.
The second issue is cash. The company currently has <12 months of cash at ~$91 million.
Price Action: ARDX shares are up 1.16% at $1.74 during the premarket session on the last check Friday.
View More Analyst Ratings for ARDX
View the Latest Analyst Ratings
See more from Benzinga
Ukraine Asserts It Does Not Take Blame For Poland Missile Attack, Crypto Exchange Gemini Suffers $485M In Outflows, FTX, Bahamas Regulator Lock Horns Over Control Of Bankruptcy Proceedings: Top Stories Thursday, Nov. 17
Despite Concerns, FDA Advisory Committee Votes In Favor Of Ardelyx's Kidney Disease Candidate
Trump Returning As President Would Be 'Holy Trinity Of Market Lubrication,' Says Anthony Scaramucci
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
